MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

MeiraGTx Holdings plc MGTX has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX).

• Xerostomia, or Dry mouth, happens when a person cannot make enough saliva (spit).
• 6 of the 7 participants who reached the Day 90 assessment reported their symptoms of dry mouth as better following treatment.
• All 6 of these participants rated changes in xerostomia scores (2 or more).
• 3 participants rated the change in xerostomia symptoms with the highest level of improvement (scores of 6 or 7)
• Improvement in xerostomia symptoms persisted through 1 year in two of the patients who reached Day 360.
• Participant 1-1 has just reached the 24-month assessment, and the highest possible score of 7 was maintained.
• Participant 2-1 reported no improvement and was the only one of the 7 participants who had no saliva production at baseline.
• The Company plans to initiate a Phase 2 study evaluating two active doses of AAV2-hAQP1 in 2H of 2022
• The Company says that no new medications for RIX have been approved in over 20 years.
• Price Action: MGTX shares closed at $17.05 on Monday.